Isis Pharmaceuticals and Eyetech Pharmaceuticals, Jefferson Medical College and the Kimmel Cancer Center, and Molecula

Jun 25, 2004

Premium

Isis Receives Macugen-Related Milestone Payment from Eyetech

Isis Pharmaceuticals said this week that it has received a $1 million milestone payment from Eyetech Pharmaceuticals in connection with Eyetech’s filing of a new drug application with US regulators for the age-related macular degeneration treatment Macugen.

Although Macugen is not an antisense agent, Eyetech licensed certain patents from Isis needed to develop, manufacture, and commercialize the drug, according to Isis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

To See More Clearly

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

Which Fish Is Which?

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

The Suspects, Too

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

This Week in PNAS

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.

Featured White Papers

Controlling Ribonuclease (RNase) with High Irradiance UV LED Light Engines

The Ultimate Guide to Mouse Clinical Trials

High Throughput RT-qPCR for Gene Expression Analysis

Mar

21

Featured Webinar

A Long-Read vs. Short-Read Platform Comparison (Part 2): Best NGS Approaches for Human Transcriptome Sequencing

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Apr

17

Featured Webinar

Biomarker Strategies for Optimizing Checkpoint Immunotherapy Treatment

This webinar will provide an overview of current biomarker strategies for guiding the use of combination checkpoint immunotherapies in blood cancers.

Menu